A detailed history of Vanguard Group Inc transactions in Armata Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 225,287 shares of ARMP stock, worth $439,309. This represents 0.0% of its overall portfolio holdings.

Number of Shares
225,287
Previous 205,753 9.49%
Holding current value
$439,309
Previous $565,000 5.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.1 - $3.3 $41,021 - $64,462
19,534 Added 9.49%
225,287 $533,000
Q2 2024

Aug 13, 2024

BUY
$2.4 - $3.9 $111,705 - $181,521
46,544 Added 29.23%
205,753 $565,000
Q1 2024

May 10, 2024

BUY
$2.81 - $4.18 $39,708 - $59,067
14,131 Added 9.74%
159,209 $665,000
Q4 2023

Feb 14, 2024

BUY
$1.95 - $3.24 $105,512 - $175,313
54,109 Added 59.48%
145,078 $470,000
Q3 2023

Nov 14, 2023

BUY
$1.1 - $4.35 $34,186 - $135,193
31,079 Added 51.89%
90,969 $272,000
Q2 2023

Aug 14, 2023

BUY
$1.14 - $1.7 $3,087 - $4,603
2,708 Added 4.74%
59,890 $68,000
Q1 2023

May 15, 2023

BUY
$1.1 - $3.58 $14,725 - $47,925
13,387 Added 30.57%
57,182 $95,000
Q4 2022

Feb 10, 2023

SELL
$0.94 - $4.16 $228,941 - $1.01 Million
-243,555 Reduced 84.76%
43,795 $54,000
Q3 2022

Nov 14, 2022

BUY
$3.12 - $4.92 $44,304 - $69,864
14,200 Added 5.2%
287,350 $1.21 Million
Q1 2022

May 13, 2022

BUY
$3.9 - $6.32 $40,560 - $65,728
10,400 Added 3.96%
273,150 $1.34 Million
Q4 2021

Feb 14, 2022

BUY
$2.96 - $5.86 $278,512 - $551,379
94,092 Added 55.79%
262,750 $1.44 Million
Q3 2021

Nov 12, 2021

BUY
$3.55 - $4.14 $4,544 - $5,299
1,280 Added 0.76%
168,658 $610,000
Q2 2021

Aug 13, 2021

BUY
$3.89 - $4.87 $651,100 - $815,130
167,378 New
167,378 $665,000

Others Institutions Holding ARMP

About Armata Pharmaceuticals, Inc.


  • Ticker ARMP
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,144,700
  • Market Cap $70.5M
  • Description
  • Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus ...
More about ARMP
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.